| Human immunodeficiency virus I infection
Isentress vs Symtuza
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Isentress vs Symtuza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSymtuza has a higher rate of injection site reactions vs Isentress based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Symtuza but not Isentress, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Isentress
Symtuza
At A Glance
Oral
Once or twice daily
HIV-1 integrase strand transfer inhibitor
Oral
Once daily
Protease inhibitor + CYP3A inhibitor + NRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (adults, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily or 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, treatment-experienced) 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, coadministration with rifampin) 800 mg (2 x 400 mg) twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 40 kg, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily, 400 mg twice daily, or 300 mg (3 x 100 mg) chewable tablets twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 25 kg) 400 mg film-coated tablet twice daily orally; weight-based chewable tablet dosing twice daily if unable to swallow tablet.
Human immunodeficiency virus I infection (pediatrics 3 kg to < 25 kg, >= 4 weeks of age) Weight-based dosing using chewable tablet or oral suspension twice daily orally (approximately 6 mg/kg/dose).
Human immunodeficiency virus I infection (neonates birth to 4 weeks, >= 2 kg) Weight-based oral suspension: once daily dosing (~1.5 mg/kg/dose) from birth to 1 week; twice daily dosing (~3 mg/kg/dose) from 1 to 4 weeks of age.
Human immunodeficiency virus I infection One tablet orally once daily with food in adults and pediatric patients weighing at least 40 kg (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide).
Contraindications
—
- Alfuzosin co-administration
- Carbamazepine, phenobarbital, or phenytoin co-administration
- Colchicine in patients with renal and/or hepatic impairment
- Rifampin co-administration
- Lurasidone or pimozide co-administration
- Dronedarone, ivabradine, or ranolazine co-administration
- Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine) co-administration
- St. John's wort co-administration
- Elbasvir/grazoprevir co-administration
- Lomitapide, lovastatin, or simvastatin co-administration
- Naloxegol co-administration
- Sildenafil when used for pulmonary arterial hypertension
- Orally administered midazolam or triazolam co-administration
Adverse Reactions
Most common (>=2%) Headache, insomnia, nausea, dizziness, fatigue.
Serious Myopathy, rhabdomyolysis, hepatitis, hepatic failure, depression including suicidal ideation and behaviors, nephrolithiasis, renal failure, hypersensitivity.
Postmarketing Thrombocytopenia, diarrhea, hepatic failure, rhabdomyolysis, cerebellar ataxia, anxiety, paranoia.
Most common (>=2%) Diarrhea, rash, nausea, fatigue, headache, abdominal discomfort, flatulence
Serious Severe acute exacerbations of hepatitis B, hepatotoxicity, severe skin reactions, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Redistribution of body fat, rhabdomyolysis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, crystal nephropathy, crystalluria
Pharmacology
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication, preventing integration of unintegrated linear HIV-1 DNA into the host cell genome; it is eliminated primarily via UGT1A1-mediated glucuronidation and does not inhibit or induce cytochrome P450 enzymes.
Symtuza is a fixed-dose combination containing darunavir (an HIV-1 protease inhibitor that prevents cleavage of Gag-Pol polyproteins), cobicistat (a CYP3A inhibitor that enhances darunavir exposure), emtricitabine (an NRTI that inhibits HIV reverse transcriptase through chain termination), and tenofovir alafenamide (an NRTI prodrug converted to tenofovir diphosphate that inhibits HIV reverse transcriptase).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Isentress
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
Symtuza
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Isentress
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Symtuza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Isentress
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Symtuza
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IsentressView full Isentress profile
SymtuzaView full Symtuza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.